A common over-the-counter supplement, frequently used by millions of older adults to manage joint discomfort, may carry unforeseen risks for those already struggling with early-stage cognitive impairment. A new study conducted by researchers at the University of Florida (UF) has identified a significant association between the use of glucosamine and an increased likelihood that mild cognitive impairment (MCI) will progress into dementia.
The findings, published in the journal Nature Metabolism, suggest that the supplement—which is widely accessible without a prescription—could potentially exacerbate the progression of neurodegenerative diseases. While the study emphasizes that these results are preliminary and require validation through rigorous human clinical trials, the research adds a compelling new layer to the scientific understanding of how metabolic disruptions may drive the development of dementia.
A Popular Supplement Under Scrutiny
Glucosamine is a staple in the medicine cabinets of older adults worldwide, prized for its purported benefits in supporting joint health and mitigating the aches associated with aging. However, given the widespread consumption of the supplement, researchers at UF sought to determine if its physiological effects might inadvertently influence Alzheimer’s disease and related dementias (ADRD).
"In the United States, there are about 7 million people living with Alzheimer’s and millions more with related dementias such as Lewy body or frontotemporal dementia," said senior author Ramon Sun, Ph.D., director of the Center for Advanced Spatial Biomolecule Research and associate director for innovation of UF’s McKnight Brain Institute. "A lot of these people actively take an over-the-counter supplement that could be making their disease progression worse."
To investigate this potential link, a research team including Yi Guo, Ph.D., and Jiang Bian, Ph.D., utilized advanced artificial intelligence to sift through deidentified patient health records from UF Health spanning the years 2012 to 2024. The study focused on a cohort of patients diagnosed with either ADRD or mild cognitive impairment. Among the groups analyzed, 8% of patients—representing 1,896 individuals with ADRD and 2,750 individuals with MCI—reported using glucosamine.
The Correlation: Glucosamine and Dementia Progression
The statistical analysis yielded findings that have prompted immediate concern within the medical research community. After adjusting for variables such as age, sex, and demographic factors, the team discovered that glucosamine use was associated with a 25% higher likelihood that patients with MCI would transition to a diagnosis of dementia.
Furthermore, the data indicated that for patients already diagnosed with ADRD, the use of glucosamine was linked to a 25% higher mortality risk, suggesting a greater probability of death within a defined period. Interestingly, the researchers did not observe this specific mortality association within the MCI cohort. This disparity leads the team to hypothesize that glucosamine’s detrimental effects may intensify once the dementia process is more firmly established within the brain.
Despite these striking statistics, the investigators are careful to note that the study does not establish a direct cause-and-effect relationship. Because the findings are derived from observational electronic health record data, there may be confounding factors—differences in lifestyle, underlying health conditions, or other behaviors—that distinguish supplement users from non-users.
"The electronic health record data are very provocative," remarked Matt Gentry, Ph.D., chair of UF’s Department of Biochemistry and Molecular Biology and a co-author of the study. "While it’s an association and not proof of causality, it does raise an important clinical question that now deserves much more attention."
Metabolic Pathways and the Role of Sugar-Tagging
Beyond the statistical correlations, the research team identified a plausible biological mechanism that could explain how glucosamine influences neurodegeneration. Their investigation focused on a metabolic pathway responsible for attaching sugar structures to proteins, a process known as glycosylation. While this process is a vital and normal component of cell biology, the researchers discovered evidence that it becomes pathologically overactive in the brains of those with Alzheimer’s disease.
According to Dr. Sun, abnormal activity in this metabolic pathway could represent a significant, previously under-explored target for future therapeutic interventions. "Our results suggest that altered metabolism is a significant contributor to Alzheimer’s progression and, in addition, addressing the metabolic defect could be an important complement to approaches focused on Alzheimer’s plaques and tangles," Sun explained.
Traditional Alzheimer’s research has long centered on two hallmarks of the disease: amyloid beta plaques, which accumulate between neurons, and tau protein tangles, which develop inside them. However, as these targets have proven notoriously difficult to address, the scientific community is increasingly looking toward secondary processes, such as metabolic dysfunction, to better understand how the disease destroys brain tissue.
To gain a granular view of these metabolic shifts, the researchers employed cutting-edge spatial technology developed in Dr. Sun’s laboratory. This innovation allows scientists to map and analyze thousands of molecules created during the body’s metabolic breakdown of food or medication. By focusing on glucosamine—a naturally occurring, sugar-related molecule capable of crossing the blood-brain barrier—the team was able to observe how the molecule interacts with the delicate biochemistry of the brain.
Because glucosamine enters the pathways that construct complex sugar structures, it appears that a brain already struggling with Alzheimer’s pathology may be uniquely vulnerable to its effects. In a healthy brain, the system might maintain equilibrium; in a diseased brain, the introduction of additional glucosamine appears to exacerbate the "sugar-tagging" process.
Experimental Evidence in Mice and Human Tissue
To validate their hypothesis, the researchers conducted experiments using genetically modified mice. The results were telling: mice treated with glucosamine exhibited a significant increase in the attachment of sugar residues to proteins within their cells. Concurrently, these mice demonstrated measurable deficits in "social memory"—the ability to recognize other animals—compared to the control group. When the scientists employed a chemical treatment to inhibit this sugar-attachment process, the mice showed improved memory performance. This suggests that the overactive sugar-tagging is not merely a bystander effect, but likely a direct contributor to the cognitive deficits observed.
The final phase of the study involved examining human brain tissue in collaboration with Stefan Prokop, M.D., of the UF Neuromedicine Brain and Tissue Bank. The analysis confirmed that brain specimens from deceased patients who had suffered from Alzheimer’s disease showed significantly higher levels of sugar attachment compared to brain tissue from healthy controls.
When synthesized, the health record data, the mouse model results, and the human tissue analysis suggest that abnormal metabolism is a fundamental component of the Alzheimer’s disease process. Dr. Gentry emphasized the gravity of these findings, noting, "Proteins are the cell’s molecular machines, and many of them need sugar tags added in just the right way to fold correctly, travel to the right place and do their jobs. What we found in Alzheimer’s is that this sugar-tagging system appears to be overactive. The Alzheimer’s brain is adding too many of these sugar structures, and this seems to contribute to the disease rather than protect against it."
For now, the researchers stop short of recommending that individuals immediately cease taking glucosamine supplements. The complex relationship between the supplement and cognitive health remains a subject of ongoing inquiry. The next critical step will be the implementation of controlled human clinical trials to definitively determine if glucosamine accelerates Alzheimer’s progression, and more importantly, to identify which specific patient populations may be at the highest risk. Until such data is available, the study serves as a poignant reminder that even common, widely used supplements warrant cautious consideration, particularly in the context of neurological health.
